ACP
CASC

Acuta Capital Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Acuta Capital Partners’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-111,667
Closed -$2.51M – 72
2015
Q2 		$2.51M Buy
+111,667
New +$1.77M 1.55% 25

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Acuta Capital Partners's CASC Position: Q3 2015 in Review

Acuta Capital Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 111,667 shares — an estimated $2.51M sold.

Acuta Capital Partners first reported a position in CASC in Q2 2015 and held it in 1 quarter. The position peaked at $2.51M in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

  • Acuta Capital Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 111,667 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $2.51M.
  • Acuta Capital Partners first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Acuta Capital Partners's Cascadian Therapeutics, Inc. position peaked at $2.51M in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on Acuta Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.